Skip to main content

Table 3 Risk of invasive breast cancer according to the HER2 Ile655Val polymorphism and common risk factors

From: A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer

Risk factor* HER2 polymorphism
  Ile/Ile, cases/controls Val/Val, cases/controls Ile/Ile, OR, 95% CI Val/Val, OR (95% CI) P
Age (years)      0.29
   <55 317/256 32/29 1 (reference) 0.78 (0.44–1.37)  
   55+ 320/295 29/40 1 (reference) 0.51 (0.29–0.89)  
Family history of breast cancer      0.24
   None 505/461 41/59 1 (reference) 0.54 (0.35–0.84)  
   Any 128/79 19/10 1 (reference) 0.92 (0.32–2.62)  
Age at menarche (years)      0.14
   <13 288/249 32/35 1 (reference) 0.88 (0.50–1.54)  
   ≥ 13 346/297 29/33 1 (reference) 0.47 (0.27–0.84)  
HRT use§      0.19
   Never/former 149/169 12/10 1 (reference) 1.24 (0.46–3.39)  
   Current 212/163 18/23 1 (reference) 0.46 (0.22–0.97)  
Recent body mass index§      0.07
   <25.3 kg/m2 159/166 14/10 1 (reference) 1.01 (0.39–2.64)  
   ≥ 25.3 kg/m2 196/163 14/25 1 (reference) 0.43 (0.20–0.91)  
Weight change since age 18 years (kg)§      0.12
   Lost 5 to gained 11 142/148 14/11 1 (reference) 1.04 (0.41–2.67)  
   Gained 12 or more 204/164 14/22 1 (reference) 0.44 (0.20–0.98)  
  1. *Risk factor cut-points based on the approximate median values for the controls; logistic regression models conditional on age and, as appropriate, adjusted for family history of breast cancer, recent alcohol consumption, parity, menopausal status, age at menopause, hormone replacement therapy use, age at menarche, height at age 25 years, weight at age 18 years, and weight change since age 18 years; P interaction using the likelihood ratio test and assuming a multiplicative model (risk factors parameterized as dichotomous variables as shown in the table for purposes of the interaction tests); § postmenopausal women only. CI, confidence interval; HRT, hormone replacement therapy; OR, odds ratio.